推荐产品
![[去氨基-Cys1, D-Arg8]-加压素 乙酸盐 水合物 ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/215/222/82da3633-80ea-463d-8b55-e99fb8e442e0/640/82da3633-80ea-463d-8b55-e99fb8e442e0.png)
![[Arg8]-Vasopressin acetate salt ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/282/717/a4c16d4f-e168-4d84-a0e3-59de3e06251e/640/a4c16d4f-e168-4d84-a0e3-59de3e06251e.png)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to tan
溶解性
DMSO: ≥15 mg/mL
创始人
Sanofi Aventis
储存温度
2-8°C
SMILES字符串
Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34
InChI
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
InChI key
GYHCTFXIZSNGJT-UHFFFAOYSA-N
基因信息
human ... AVPR2(554)
应用
Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice.
生化/生理作用
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.
Tolvaptan is a potent, orally active non-peptide vasopressin V2 receptor antagonist.
特点和优势
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
制备说明
Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
[Adverse effects of cardiovascular agents in Japan--update 2012].
Yayoi Tetsuou Tsukada
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 6, 239-244 (2012-11-20)
Mohamed El-Shabrawy et al.
Pharmacology research & perspectives, 8(5), e00659-e00659 (2020-10-01)
Cyclophosphamide (CP) is a chemotherapeutic agent which is extensively used in the treatment of multiple neoplastic and nonneoplastic diseases like breast cancer, lymphomas, systemic lupus erythematosus, and multiple sclerosis. Dose-limiting side effects, mainly nephrotoxicity is a major problem hindering its
Christine Yu et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 11(1), 3-11 (2013-02-08)
Hyponatremia has long been associated with worsened clinical outcomes in patients with cirrhosis and those awaiting liver transplant. However, in the last several years, new modalities of therapy, particularly aquaretics known as "vaptans," and comprehensive prognostic models have been increasingly
Teruhiko Imamura et al.
International heart journal, 54(2), 115-118 (2013-05-17)
Tolvaptan (TLV), a vasopressin type 2 receptor antagonist, has been demonstrated to be effective in patients with decompensated heart failure (HF) refractory to incremental doses of diuretics, but the responsiveness has not always been predictable. We have recently proposed that
Kiyotaka Watanabe et al.
Journal of cardiology, 60(6), 462-469 (2012-10-17)
We evaluated the short-term effects of low-dose tolvaptan treatment on hemodynamic parameters in patients with chronic heart failure (HF). We studied 22 patients (69 ± 10 years) with chronic HF and excess fluid retention despite receiving appropriate medical therapy, including
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门